Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics

The Israeli mask company Sonovia has released a report from a leading Italian textile-testing laboratory showing that its fabric eliminates the COVID-19 Delta variant particles with over 99.95% effectiveness.

The lab is next expected to test the fabric against the MU strain, which carries several mutations to the spike gene, and is labeled a “variant of interest” by the World Health Organization, said Sonovia Chief Technology Officer Liat Goldhammer-Steinberg.

The MU strain has not yet entered Israel, according to any official reports, but Health Ministry officials have warned of its potential negative impact.

VisMederi is a commercial research laboratory located in Italy. It says on its website that the company “currently receives orders worldwide in the field of vaccines, where it conducts analytical testing of biological samples and validation of bioanalytical methods for the pharmaceutical industry.”

Read more | >

“Our study points to sex-and environment-specific effects of a common genetic variant. In the mice, we observed that Ghrd3 leads to a ‘female-like’ expression pattern of dozens of genes in male livers under calorie restriction, which potentially leads to the observed size reduction,” Saitou says.

“Females, already smaller in size, may suffer from negative evolutionary consequences if they lose body weight. Thus, it is a reasonable and also very interesting hypothesis that a genetic variant that may affect response to nutritional stress has evolved in a sex-specific manner,” Mu says.

A new study delves into the evolution and function of the human growth hormone receptor gene, and asks what forces in humanity’s past may have driven changes to this vital piece of DNA.

The research shows, through multiple avenues, that a shortened version of the gene—a known as GHRd3—may help people survive in situations where resources are scarce or unpredictable.

Findings will be published on Sept. 24 in Science Advances.

Read more | >

Leave it to the Japanese to come up with technology-induced fruit

A Tokyo-based startup called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The result was a Sicilian Rouge High GABA which contains high levels of gamma-aminobutyric acid (GABA), an amino acid that is believed to have lower blood pressure and help in relaxation.

The company was able to add high levels of GABA by removing an inhibitory domain within the tomato’s genome to enable the high production of GABA. According to Shimpei Takeshita, President of Sanatech Seed and Chief Innovation Officer of Pioneer EcoScience, the company was given permission to commercialize the genetically altered Sicilian Rouge GABA variety last December. The contract farmers had been growing them ever since and now these tomatoes are finally ready to hit the stores and become a useful product.

Read more | >

A sperm’s task may appear straightforward; after all, all it needs to do is swim to an egg and insert genetic material. However, in some cases, a healthy sperm’s inability to swim may result in infertility, which affects around 7 percent of all males.

This condition is called asthenozoospermia, and there is currently no cure. However, one study conducted in 2016 and published in the journal Nano Letters has set the example for what could be possible in the future: A team of researchers from the Institute for Integrative Nanosciences at IFW Dresden in Germany developed tiny motors that can make sperm swim better as they make their way to an egg, essentially acting as a taxi.

These so-called “spermbots” basically consist of a tiny micromotor, which is basically a spiraling piece of metal that wraps around the sperm’s tail. Serving as an “on-board power supply”, the motor navigates the sperm via a magnetic field, helping the sperm swim to the egg with ease. When the sperm makes contact with the egg for fertilization, the motor slips right off, and the magnetic field doesn’t harm any of the cells involved, making it ideal for usage on living tissue, according to the researchers.

Read more | >

As this is the first report of neuro-inflammation in Kleefstra syndrome, the next step is to find out if it also occurs in the human condition. Shinkai believes the chances are high and says he would not be surprised if other neurological diseases caused by epigenetic dysregulation were also related to abnormal inflammation in the brain.

Researchers at the RIKEN Cluster for Pioneering Research (CPR) in Japan report that Kleefstra syndrome, a genetic disorder that leads to intellectual disability, can be reversed after birth in a mouse model of the disease. Published in the scientific journal iScience, the series of experiments led by Yoichi Shinkai showed that postnatal treatment resulted in improved symptoms, both in the brain and in behavior.

Normally, we get two good copies of most genes, one from each parent. In Kleefstra , one copy of the EHMT1 gene is mutated or missing. This leads to half the normal amount of GLP, a protein whose job is to control genes related to brain development through a process called H3K9 methylation. Without enough GLP, H3K9 methylation is also reduced, and the connections between neurons in the brain do not develop normally. The result is and autistic-like symptoms. “We still don’t know if Kleefstra syndrome is a curable disease after birth or how this epigenetic dysregulation leads to the ,” says Shinkai. “Our studies in have provided new information about what causes the behavioral abnormalities associated with the syndrome and have shown that a cure is a real possibility in the future.”

Reasoning that extra GLP might be an , the researchers performed a series of experiments in mice that were engineered to have only one good copy of the EHMT1 gene. The brains of these mice show characteristics of the human condition, including 40% less GLP and 30% less H3K9 methylation. The mice also display several behaviors seen in humans with Kleefstra syndrome, such as reduced locomotion and greater anxiety. After each experiment, the researchers measured these factors and compared them to normal mice to see if the treatment had been effective.

Read more | >

The pharmaceuticals firm GSK has struck a five-year partnership with King’s College London to use artificial intelligence to develop personalised treatments for cancer by investigating the role played by genetics in the disease.

The tie-up, which involves 10 of the drug maker’s artificial intelligence experts working with 10 oncology specialists from King’s across their labs, will use computing to “play chess with cancer”, working out why only a fifth of patients respond well to immuno-oncology treatments.

Read more | >

CRISPR technology offers the promise to cure any human genetic disease with gene editing; which one will be the first?

CRISPR-Cas9 was first used as a gene-editing tool in 2012. In just a few years, the technology has exploded in popularity thanks to its promise of making gene editing much faster, cheaper, and easier than ever before.

CRISPR is short for ‘clustered regularly interspaced short palindromic repeats.’ The term makes reference to a series of repetitive patterns found in the DNA of bacteria that form the basis of a primitive immune system, defending them from viral invaders by cutting their DNA.

Read more | >

Ancient DNA extracted from human bones has rewritten early Japanese history by underlining that modern day populations in Japan have a tripartite genetic origin—a finding that refines previously accepted views of a dual genomic ancestry.

Twelve newly sequenced ancient Japanese genomes show that modern day populations do indeed show the genetic signatures of early indigenous Jomon hunter-gatherer-fishers and immigrant Yayoi farmers—but also add a third genetic component that is linked to the Kofun peoples, whose culture spread in Japan between the 3rd and 7th centuries.

Read more | >